Johnson & Johnson (JNJ) Stake Boosted by Randolph Co Inc

Randolph Co Inc grew its stake in shares of Johnson & Johnson (NYSE:JNJ) by 0.1% in the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 148,361 shares of the company’s stock after acquiring an additional 190 shares during the quarter. Johnson & Johnson comprises approximately 3.7% of Randolph Co Inc’s portfolio, making the stock its 9th biggest position. Randolph Co Inc’s holdings in Johnson & Johnson were worth $19,627,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other large investors also recently modified their holdings of the company. Lenox Wealth Advisors Inc. boosted its position in shares of Johnson & Johnson by 0.6% during the second quarter. Lenox Wealth Advisors Inc. now owns 876 shares of the company’s stock valued at $116,000 after buying an additional 5 shares during the last quarter. Harel Insurance Investments & Financial Services Ltd. boosted its position in shares of Johnson & Johnson by 241.0% during the first quarter. Harel Insurance Investments & Financial Services Ltd. now owns 1,190 shares of the company’s stock valued at $149,000 after buying an additional 841 shares during the last quarter. Ullmann Financial Group Inc. purchased a new stake in shares of Johnson & Johnson during the first quarter valued at $186,000. Taylor Wealth Management Partners boosted its position in shares of Johnson & Johnson by 19.8% during the first quarter. Taylor Wealth Management Partners now owns 1,510 shares of the company’s stock valued at $188,000 after buying an additional 250 shares during the last quarter. Finally, Hutchens Investment Management Inc purchased a new stake in shares of Johnson & Johnson during the first quarter valued at $204,000. Hedge funds and other institutional investors own 65.90% of the company’s stock.

In related news, VP Paulus Stoffels sold 102,692 shares of the business’s stock in a transaction dated Monday, July 24th. The stock was sold at an average price of $133.14, for a total value of $13,672,412.88. Following the transaction, the vice president now owns 230,342 shares in the company, valued at approximately $30,667,733.88. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, VP Dominic J. Caruso sold 82,591 shares of the business’s stock in a transaction dated Thursday, July 20th. The shares were sold at an average price of $136.72, for a total value of $11,291,841.52. Following the completion of the transaction, the vice president now owns 226,693 shares in the company, valued at approximately $30,993,466.96. The disclosure for this sale can be found here. Insiders own 0.19% of the company’s stock.

Johnson & Johnson (NYSE:JNJ) last issued its quarterly earnings results on Tuesday, July 18th. The company reported $1.83 earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of $1.79 by $0.04. The firm had revenue of $18.84 billion for the quarter, compared to analysts’ expectations of $18.94 billion. Johnson & Johnson had a return on equity of 26.76% and a net margin of 22.52%. The firm’s revenue for the quarter was up 1.9% on a year-over-year basis. During the same quarter in the previous year, the firm posted $1.74 EPS.

JNJ has been the topic of several recent analyst reports. BidaskClub raised Johnson & Johnson from a “buy” rating to a “strong-buy” rating in a research report on Saturday, June 17th. Royal Bank Of Canada reaffirmed a “buy” rating and set a $128.00 price objective on shares of Johnson & Johnson in a research report on Thursday, June 15th. Atlantic Securities cut Johnson & Johnson from a “neutral” rating to an “underweight” rating and set a $113.00 price objective on the stock. in a research report on Friday, July 21st. Jefferies Group LLC reaffirmed a “hold” rating and set a $145.00 price objective (up from $140.00) on shares of Johnson & Johnson in a research report on Friday, July 14th. Finally, Citigroup Inc. initiated coverage on Johnson & Johnson in a research report on Monday, September 25th. They set a “neutral” rating and a $140.00 price objective on the stock. Five research analysts have rated the stock with a sell rating, eight have assigned a hold rating and ten have assigned a buy rating to the stock. Johnson & Johnson presently has an average rating of “Hold” and an average target price of $135.98.

WARNING: “Johnson & Johnson (JNJ) Stake Boosted by Randolph Co Inc” was reported by Markets Daily and is the sole property of of Markets Daily. If you are accessing this article on another website, it was illegally stolen and reposted in violation of US and international trademark and copyright laws. The original version of this article can be viewed at https://www.themarketsdaily.com/2017/10/13/johnson-johnson-jnj-stake-boosted-by-randolph-co-inc.html.

Johnson & Johnson Company Profile

Johnson & Johnson is a holding company, which is engaged in the research and development, manufacture and sale of a range of products in the healthcare field. It operates through three segments: Consumer, Pharmaceutical and Medical Devices. Its primary focus is products related to human health and well-being.

Institutional Ownership by Quarter for Johnson & Johnson (NYSE:JNJ)

Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply